Acuitas Lighthouse is the first service of its kind to use genomics and informatics to predict antibiotic resistance and it is being developed to provide real-time suggestions for treatment. Drawing on genotype and phenotype data from 15,000 clinical isolates collected from hospitals worldwide, it predicts antibiotic resistance in specific microbes and generates simple reports that tell which drugs are likely to be effective and which ones are likely to be ineffective. Data from the Acuitas AMR Gene Panel (RUO) or from OpGen’s Acuitas Whole Genome Sequencing (RUO) service can be loaded into the Acuitas Lighthouse to produce instant antibiotic resistance prediction reports.
Accurate and Reliable Antibiotic Resistance Predictions
Average Sensitivity and Specificity for Genotypic Prediction of Phenotypic Resistance
|Organism||Avg. Sensitivity||Avg. Specificity||Antibiotics|
|E. coli||91%||90%||Aztreonam, Cefazolin, Cefepime, Cefotaxime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Levofloxacin, Gentamicin, Tobramycin, Trimethoprim-sulfamethoxazole, Piperacillin|
|K. pneumoniae||90%||83%||Aztreonam, Cefazolin, Cefepime, Cefotaxime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Levofloxacin, Imipenem, Gentamicin, Tobramycin, Trimethoprim-sulfamethoxazole|
|P. mirabilus||81%||89%||Ampicillin, Cefazolin, Cefotaxime, Ceftazidime, Ceftriaxone, Tobramycin, Trimethoprim-sulfamethoxazole, Piperacillin|
|P. aeruginosa||85%||82%||Ciprofloxacin, Levofloxacin|
Algorithm Training Set Data
7,527 isolates, geographically diverse
Certain combinations of the 4 pathogens and the antibiotics Ampicillin, Imipenem, Meropenem, Ertapenem, Aztreonam, Cefepime, Ceftazidime, Gentamicin, and Tobramycin are analyzed by a different model and only resistance is reported when specific antibiotic resistance genes are detected. These combinations are not included in the table above.
How it works
2.5 Hours Total Time